Montelukast: Difference between revisions
No edit summary |
No edit summary |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
[[File:Montelukast.svg|Montelukast|thumb]] | |||
[[File:Montelukast 3D ball-and-stick.png|Montelukast 3D ball-and-stick|thumb]] | |||
Montelukast is an orally available leukotriene receptor antagonist which is widely used for the prophylaxis and chronic treatment of [[asthma]]. It is marketed as [[Singulair]]. | Montelukast is an orally available leukotriene receptor antagonist which is widely used for the prophylaxis and chronic treatment of [[asthma]]. It is marketed as [[Singulair]]. | ||
{{intro}} | {{intro}} | ||
| Line 12: | Line 14: | ||
{{se}} | {{se}} | ||
Common side effects include dyspepsia, abdominal discomfort, asthenia, [[headache]], [[dizziness]], [[fatigue]] and fever. | Common side effects include dyspepsia, abdominal discomfort, asthenia, [[headache]], [[dizziness]], [[fatigue]] and fever. | ||
{{ | {{Asthma and copd rx}} | ||
{{ | {{Leukotriene signaling modulators}} | ||
{{ | {{Merck&Co}} | ||
{{Portal bar | Medicine}} | |||
[[Category:Alkene derivatives]] | |||
[[Category:Chloroarenes]] | |||
[[Category:Cyclopropanes]] | |||
[[Category:CYP2C8 inhibitors]] | |||
[[Category:Leukotriene antagonists]] | |||
[[Category:Drugs developed by Merck & Co.]] | |||
[[Category:Quinolines]] | |||
[[Category:Thioethers]] | |||
[[Category:Phenylene compounds]] | |||
Latest revision as of 02:15, 22 March 2025
Montelukast is an orally available leukotriene receptor antagonist which is widely used for the prophylaxis and chronic treatment of asthma. It is marketed as Singulair.
Information about Montelukast[edit]
Montelukast is an orally available leukotriene receptor antagonist which is widely used for the prophylaxis and chronic treatment of asthma.
Liver safety of Montelukast[edit]
It has been linked to rare cases of clinically apparent liver injury.
Mechanism of action of Montelukast[edit]
Montelukast (mon" te loo' kast) is a leukotriene receptor antagonist that binds to the CysLT1 and CysLT2 receptors, thereby interfering with inflammatory pathways that are involved in the pathogenesis of asthma and allergic rhinitis. Montelukast has been shown to reduce symptoms of asthma and allergic rhinitis and prevent acute attacks.
FDA approval information for Montelukast[edit]
Montelukast was approved for use in the United States in 1998 and is widely used with more than 20 million prescriptions being filled yearly. Current indications for montelukast include prophylaxis and chronic treatment of asthma, prevention of exercise induced bronchoconstriction and allergic rhinitis.
Dosage and administration for Montelukast[edit]
Montelukast is available in several generic forms and under the commercial name Singulair. The recommended dosage for adults is 10 mg once daily. Lower doses and chewable tablets are recommended for pediatric patients.
Side effects of Montelukast[edit]
Common side effects include dyspepsia, abdominal discomfort, asthenia, headache, dizziness, fatigue and fever.
| Drugs for obstructive airway diseases: asthma/COPD (R03) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
| Leukotriene signaling modulators | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| Merck & Co., Inc. | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
